| PHEMCE Broad Spectrum Antibiotic Working Group |
Committee, Work group, Advisory group, or Task Force |
ASPR, CDC, FDA |
NIAID |
Working group on broad spectrum antibiotics. |
| PHS Technology Transfer Policy Board |
Committee, Work group, Advisory group, or Task Force |
CDC, FDA |
NIAID |
The purpose of the PHS Technology Transfer Policy Board (TTPB) is to serve as the principal advisory board to the National Institutes of Health (NIH) as lead agency in the PHS technology transfer program, the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), in establishing PHS technology transfer policies and modifying existing policies, as applicable. |
| Physical Activity Guidelines Advisory Committee |
Committee, Work group, Advisory group, or Task Force |
OASH, CDC |
NCI, NIAMS |
The Physical Activity Guidelines is an essential resource for health professionals and policy makers. It includes recommendations for Americans ages 3 years and over — including people at increased risk of chronic disease — and provides evidence-based advice on how physical activity can help promote health and reduce the risk of chronic disease.The Guidelines serves as the primary, authoritative voice of the federal government for evidence-based guidance on physical activity, fitness, and health for Americans. ODPHP leads the development of the Guidelines in collaboration with the Centers for Disease Control and Prevention, the National Institutes of Health, and the President’s Council on Sports, Fitness & Nutrition. |
| Physical Activity Guidelines Executive Committee |
Committee, Work group, Advisory group, or Task Force |
AHRQ, CDC, OASH |
OD/DPCPSI/ODS |
The Executive Committee will support the 2028 Physical Activity Guidelines Advisory Committee and the 2028 U.S. Physical Activity Guidelines. |
| Population Assessment of Tobacco and Health (PATH) Study |
Health Survey |
FDA |
NIDA |
The PATH Study is a national longitudinal cohort study that will follow an estimated 59,000 US household residents ages 12 years and older for at least three years. |
| PRAMS Interagency Workgroup |
Committee, Work group, Advisory group, or Task Force |
CDC, CMS, HRSA |
NICHD |
Support team of PRAMS users as they build their internal capacity to link MCH data sets and inform their future programming. |
| PRAMS Multi-Jurisdiction Data Linkage Learning Community |
Committee, Work group, Advisory group, or Task Force |
CDC, CMS, HRSA |
NICHD |
Support teams of PRAMS users building their internal capacity to link MCH data sets and inform their future programming. |
| Precision Oncology Interest Group |
Committee, Work group, Advisory group, or Task Force |
FDA |
NCATS, NCI, NHLBI, NIAID, NIAMS, NIBIB, NIDDK, NINDS, OD |
The POIG, and its attendant listserv will aim to foster effective communication across the basic and clinical research oncology communities, to harness the translational powers of the NIH to advance precision therapy across cancers. The goals of the POIG are to discuss, plan, implement and execute the current CCR initiative to perform standardized genomic analyses (RNA-SEQ, exome-SEQ, methylation analysis) on a large cohort of NCI patients, with the goal of using these data to drive collaborative predictive and prognostic biomarker discovery and precision therapy strategies for improving patient outcomes, to discuss and implement best sample acquisition and management practices to learn the most from any precious patient material, to discuss and implement the best technologies and informatics to help us discover candidates for targeted therapies with the goal of maximizing favorable outcomes for oncology patients, and to rationally design clinical trials in oncology with a focus on precise therapies that have the potential to maximize benefit and minimize side effects. |
| Preclinical Assessment of Phage Therapy for Pathogen Decolonization |
Research Initiative |
FDA |
NIAID |
This project addresses key regulatory considerations relevant to using bacteriophages for decolonization of the drug-resistant nosocomial pathogens, vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). These include characterizing pathogen resistance to phage, defining phage mixtures ("cocktails") to circumvent resistance, optimizing mouse models to evaluate pathogen decolonization, and identifying endpoints that support claims for clinical benefit (e.g., reduced risk of disease transmission). |
| Pregnancy and Birth to 24 months (P/B-24) Project |
Committee, Work group, Advisory group, or Task Force |
CDC, FDA, HRSA, OS |
NCI, NHLBI, NICHD, NIEHS, NINR |
In 2012, the US Department of Agriculture (USDA) and Department of Health and Human Services (HHS) initiated a project informally called the “B-24 project.” This multi-phase project was originally intended to conclude in 2018 with information that could help the Departments develop dietary recommendations for infants and toddlers for release separate from the Dietary Guidelines. The first phase was completed in 2012-2013. In February 2014, Congress passed the Agricultural Act of 2014, also known as the Farm Bill, mandating that the Dietary Guidelines expand to include dietary guidance for infants and toddlers (from birth to age 24 months), as well as women who are pregnant, beginning with the 2020-2025 edition. Thus, USDA and HHS adjusted the purpose, timeline, and scope of the project. Now called the “Pregnancy and Birth to 24 Months project” or “P/B-24 project” to reflect the addition of pregnant women, this project is a joint initiative led by USDA and HHS in collaboration with programmatic and scientific experts. Rather than concluding in 2018 with dietary recommendations, the goal of the current project is to begin examining topics of public health importance for women who are pregnant and infants and toddlers from birth to 24 months of age. The findings from this work will be made publicly available at the completion of the project. https://www.fns.usda.gov/resource/pregnancy-and-birth-24-months |